← All health signals
Wellness turn

The Protocol Life

One man’s longevity regimen has become a product line, sold in parts to anyone and whole for $1 million a year, while many longevity scientists call it hype.

What is it?

One wealthy man’s private regimen has become a product: Bryan Johnson shares and sells his protocol so people can try parts of it, and offers the exact version for $1 million a year. Whether buyers are following clinical evidence or a well-documented performance stays the open part.

Why now?

The body gets sold like a product with tiers: parts for anyone, a $60,000 supported tier, and the whole protocol for three buyers at $1 million. Many longevity scientists call it hype and unscientific advice. The structure rewards purchase more than evidence.

Who’s building it?

A founder selling his own protocol in tiers, self-experimenters buying parts of it, and scientists calling it hype.

Self-experimentersSupplement suppliersLongevity scientistsCliniciansDigital-health startups
The full read
Why now, who is building it, where the market goes, and what stays unsettled.
Get weekly →
01 · The market
Who’s in it
Builders — self-experimenters assembling protocols, and suppliers behind each compound.
Buyers — buyers trying parts of a public protocol, or paying for the exact version.
Gatekeepers — clinicians left reacting to a stack a patient already built and started.
What’s at stake
A $60,000 supported tier already sits between wellness and medicine — clinics could formalise it, or the stack keeps outrunning them.
Liability stays unresolved once therapies combine outside any approved use.
Optimising one’s biology becomes a visible identity marker, not medicine.
What’s unsettled
Whether clinical evidence catches up with the pace protocols get revised.
Who carries liability when a self-assembled combination causes real harm.
Whether open communities end up professionalising this practice or simply accelerate risky copying at scale.
02 · How the demand matureda progression, not a timeline
Novelty
One visible figure’s regimen draws early, curious imitators willing to self-experiment.
Retention
Every revision gives adopters a fresh reason to stay engaged with suppliers.
Willingness to pay
A $1 million exact protocol and a $60,000 supported tier put a price on the regimen.
Category
A service tier could form between consumer wellness and regulated medicine, run by clinics rather than a founder.
03 · Where the market goesthe forks, not a prediction
→Professionalised or self-run — decided by whether clinics formalise test-prescribe-monitor oversight, or open communities keep outpacing any clinical structure.
→Scientists’ charge of hype could slow buyers, or simply sit beside a protocol that keeps selling.
→Liability could concentrate on suppliers, on clinicians, or stay diffused across an unsupervised stack.
→The regimen could keep moving through a founder’s own sales, ahead of any regulation.
Everything here turns on evidence: whether a modular, constantly revised protocol can ever catch up to the clinical proof many longevity scientists say it lacks.
04 · The Longevity Dividend deskadjacent markets, moving now
The Ageing Ledger
Repeated biomarker readings beat one snapshot.
Longitudinal epigenetic clocks predict survival better than one reading.
Nature Aging
The Age You Earn
Faster biological clocks now predict real mortality.
Faster epigenetic clocks predict mortality risk.
Nature Aging
Longevity as Lifestyle
Serious capital now backs cellular reprogramming research.
Altos Labs raised $3B to fund cellular reprogramming.
MIT Technology Review
05 · The Wire
01
Johnson says he shares and sells his protocol for others to try
TIME ↗
02
Johnson’s ‘exact protocol’ is offered at $1 million a year
TechCrunch ↗
The panel on this signal
They agreed on
–The protocol’s structure rewards revision and continued engagement, not necessarily the clinical evidence behind any given combination.
–The protocol is sold as a product, from parts to a $1 million exact version.
–Liability for these self-assembled combinations remains genuinely unresolved across suppliers, clinicians, and the adopters themselves.
The clinical specialist disagreed on
–Scientists publicly calling a protocol hype typically functions as a credibility marker within its community rather than a deterrent; criticism framed this way tends to be absorbed into the narrative instead of slowing uptake.
Know more about the method →
✦How this signal was built
01 · Panel
A Delphi panel of 4 AI analysts, each reasoning independently.
→
02 · Debate
They challenge and revise each other’s reads over two rounds.
→
03 · Evidence
Every claim is tied to a cited, linked source on The Wire.
→
04 · Synthesis
A moderator writes it into one read, disagreement and all.